ImpediMed Limited
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue compositi… Read more
ImpediMed Limited (IPDQF) - Net Assets
Latest net assets as of June 2025: $20.50 Million USD
Based on the latest financial reports, ImpediMed Limited (IPDQF) has net assets worth $20.50 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($41.66 Million) and total liabilities ($21.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $20.50 Million |
| % of Total Assets | 49.2% |
| Annual Growth Rate | 0.3% |
| 5-Year Change | -19.67% |
| 10-Year Change | -75.96% |
| Growth Volatility | 68.4 |
ImpediMed Limited - Net Assets Trend (2007–2025)
This chart illustrates how ImpediMed Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ImpediMed Limited (2007–2025)
The table below shows the annual net assets of ImpediMed Limited from 2007 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $20.50 Million | -49.69% |
| 2024-06-30 | $40.74 Million | -33.08% |
| 2023-06-30 | $60.88 Million | +19.27% |
| 2022-06-30 | $51.04 Million | +100.06% |
| 2021-06-30 | $25.51 Million | -6.75% |
| 2020-06-30 | $27.36 Million | +73.34% |
| 2019-06-30 | $15.79 Million | -56.16% |
| 2018-06-30 | $36.00 Million | -38.77% |
| 2017-06-30 | $58.80 Million | -31.03% |
| 2016-06-30 | $85.25 Million | +144.72% |
| 2015-06-30 | $34.84 Million | +157.44% |
| 2014-06-30 | $13.53 Million | +27.73% |
| 2013-06-30 | $10.59 Million | -38.80% |
| 2012-06-30 | $17.31 Million | -16.31% |
| 2011-06-30 | $20.68 Million | -6.96% |
| 2010-06-30 | $22.23 Million | +120.82% |
| 2009-06-30 | $10.07 Million | -18.16% |
| 2008-06-30 | $12.30 Million | -36.61% |
| 2007-06-30 | $19.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ImpediMed Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32238038100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $336.15 Million | 1640.06% |
| Other Comprehensive Income | $38.54 Million | 188.03% |
| Total Equity | $20.50 Million | 100.00% |
ImpediMed Limited Competitors by Market Cap
The table below lists competitors of ImpediMed Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NISSAN SECURITIES GROUP
F:OH5
|
$36.01 Million |
|
Neffs Bancorp Inc
PINK:NEFB
|
$36.01 Million |
|
Openbase Inc
KQ:049480
|
$36.01 Million |
|
Value8 N.V
AS:VALUE
|
$36.01 Million |
|
Daily Polymer
TWO:4716
|
$35.99 Million |
|
Ramssol Group Bhd
KLSE:0236
|
$35.97 Million |
|
Ten Ren Tea Co Ltd
TW:1233
|
$35.95 Million |
|
B1Q
F:B1Q
|
$35.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ImpediMed Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 40,743,000 to 20,496,000, a change of -20,247,000 (-49.7%).
- Net loss of 23,237,000 reduced equity.
- Other comprehensive income increased equity by 2,990,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-23.24 Million | -113.37% |
| Other Comprehensive Income | $2.99 Million | +14.59% |
| Total Change | $- | -49.69% |
Book Value vs Market Value Analysis
This analysis compares ImpediMed Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.97x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.09x to 1.97x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-06-30 | $0.23 | $0.02 | x |
| 2008-06-30 | $0.17 | $0.02 | x |
| 2009-06-30 | $0.10 | $0.02 | x |
| 2010-06-30 | $0.18 | $0.02 | x |
| 2011-06-30 | $0.13 | $0.02 | x |
| 2012-06-30 | $0.10 | $0.02 | x |
| 2013-06-30 | $0.05 | $0.02 | x |
| 2014-06-30 | $0.06 | $0.02 | x |
| 2015-06-30 | $0.12 | $0.02 | x |
| 2016-06-30 | $0.25 | $0.02 | x |
| 2017-06-30 | $0.15 | $0.02 | x |
| 2018-06-30 | $0.09 | $0.02 | x |
| 2019-06-30 | $0.04 | $0.02 | x |
| 2020-06-30 | $0.05 | $0.02 | x |
| 2021-06-30 | $0.02 | $0.02 | x |
| 2022-06-30 | $0.03 | $0.02 | x |
| 2023-06-30 | $0.03 | $0.02 | x |
| 2024-06-30 | $0.02 | $0.02 | x |
| 2025-06-30 | $0.01 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ImpediMed Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -113.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -182.62%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 2.03x
- Recent ROE (-113.37%) is below the historical average (-71.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -79.30% | -422.00% | 0.16x | 1.18x | $-10.98 Million |
| 2009 | -139.34% | -468.85% | 0.23x | 1.30x | $-15.03 Million |
| 2010 | -51.29% | -313.33% | 0.15x | 1.12x | $-13.62 Million |
| 2011 | -71.66% | -381.32% | 0.17x | 1.10x | $-16.89 Million |
| 2012 | -71.30% | -419.08% | 0.15x | 1.13x | $-14.07 Million |
| 2013 | -79.89% | -309.70% | 0.23x | 1.12x | $-9.52 Million |
| 2014 | -58.64% | -225.36% | 0.24x | 1.11x | $-9.29 Million |
| 2015 | -42.47% | -305.47% | 0.13x | 1.09x | $-18.28 Million |
| 2016 | -30.47% | -448.63% | 0.06x | 1.06x | $-34.51 Million |
| 2017 | -46.89% | -478.17% | 0.09x | 1.09x | $-33.45 Million |
| 2018 | -75.48% | -566.48% | 0.11x | 1.16x | $-30.77 Million |
| 2019 | -152.82% | -588.65% | 0.18x | 1.43x | $-25.70 Million |
| 2020 | -78.13% | -375.43% | 0.17x | 1.21x | $-24.11 Million |
| 2021 | -81.16% | -247.89% | 0.24x | 1.34x | $-23.26 Million |
| 2022 | -38.94% | -189.37% | 0.18x | 1.15x | $-24.98 Million |
| 2023 | -33.71% | -180.90% | 0.17x | 1.13x | $-26.61 Million |
| 2024 | -48.57% | -196.86% | 0.21x | 1.15x | $-23.86 Million |
| 2025 | -113.37% | -182.62% | 0.31x | 2.03x | $-25.29 Million |
Industry Comparison
This section compares ImpediMed Limited's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ImpediMed Limited (IPDQF) | $20.50 Million | -79.30% | 1.03x | $36.00 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |